Roche’s Cobas TV/MG Test Receives FDA’s 510 (k) Clearance for the Detection of Sexually Transmitted Diseases

 Roche’s Cobas TV/MG Test Receives FDA’s 510 (k) Clearance for the Detection of Sexually Transmitted Diseases

Roche’s Cobas TV/MG Test Receives FDA’s 510 (k) Clearance for the Detection of Sexually Transmitted Diseases

Shots:

  • Roche has received 510(k) clearance for its Cobas TV/MG test runs on Cobas 6800/8800 System to detect Trichomonas vaginalis (TV) and/or Mycoplasma genitalium (MG) DNA in both symptomatic and asymptomatic patients
  • The addition of Cobas TV/MG test expands the testing menu on the Cobas 6800/8800 Systems and has been validated to use with multiple specimens including male/female urine, endocervical swabs and vaginal swabs
  • The combination of Cobas TV/MG with Cobas Chlamydia trachomatis (CT)/ Neisseria gonorrhoeae (NG) based on PCR technology, used for the detection of CT & NG, providing high throughput solutions supporting the molecular testing needs

Click here to read full press release/ article | Ref: Roche | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post